| Literature DB >> 30367604 |
Su Hwan Lee1, Soo Jung Kim1, Yoon Hee Choi2, Jin Hwa Lee1, Jung Hyun Chang1, Yon Ju Ryu3.
Abstract
BACKGROUND: There has been a steady increase in the aging population and an increase in the need for long-term care beds in institutions and hospitals (LTCHs) in Korea. The aim of this study was to investigate prognosis and to identify factors contributing to mortality of critically ill patients with respiratory problems who were directly transferred to intensive care units (ICU) from LTCHs.Entities:
Keywords: Intensive care units; Long-term care; Nursing homes; Pneumonia
Mesh:
Year: 2018 PMID: 30367604 PMCID: PMC6203994 DOI: 10.1186/s12877-018-0950-9
Source DB: PubMed Journal: BMC Geriatr ISSN: 1471-2318 Impact factor: 3.921
Fig. 1Trends in the number of patients with respiratory problems admitted to the ICU from long-term care beds in institutions and hospitals
Demographic and clinical characteristics of the study population
| Characteristics | |
|---|---|
| Male sex | 71 (64) |
| Age, years | 79 ± 10 |
| BMI, kg/m2 | 20.7 ± 4.0 |
| APACHE II score | 24.9 ± 6.7 |
| Charlson Comorbidity Index | 2.45 ± 1.67 |
| ICU length of stay, days | 11.8 ± 1.3 |
| Hospital length of stay, days | 24.5 ± 3.0 |
| Permanent tracheostomy status | 28 (25.2) |
| Nasogastric tube insertion status | 38 (34.2) |
| Bedridden status | 50 (45) |
| ARDS | 29 (26.1) |
| Use of antibiotics within 3 months | 49 (44.1) |
| Blood culture positive | 25 (22.5) |
| Sputum culture positive | 66 (59.5) |
| MDR pathogen (sputum culture or blood culture) | 53 (47.7) |
| Major cause of admission | |
| Pneumonia | 98 (88.3) |
| Pulmonary thromboembolism | 4 (3.6) |
| Pulmonary tuberculosis | 3 (2.7) |
| Lung abscess | 1 (0.9) |
| Idiopathic pulmonary fibrosis | 1 (0.9) |
| Lung cancer | 1 (0.9) |
| COPD exacerbation | 1 (0.9) |
| Asphyxia | 1 (0.9) |
| Hemoptysis | 1 (0.9) |
Values are presented as numbers (percentages) and as mean ± standard deviation, unless otherwise indicated. BMI, body mass index; APACHE, acute physiology and chronic health evaluation; ICU, intensive care unit; ARDS, acute respiratory distress syndrome; MDR, multiple-drug-resistant; COPD, Chronic Obstructive Pulmonary Disease
Predictors of mortality between survivors and non-survivors
| Variable | Univariate | Multivariate | |||
|---|---|---|---|---|---|
| Survivor ( | Non-survivor ( |
|
|
| |
| Male sex | 55 (61.8) | 16 (72.7) | 0.339 | 0.31 (0.06–1.75) | 0.186 |
| Age, years | 78 (69.5–83.0) | 81.5 (74.3–86.3) | 0.064 | 1.07 (0.96–1.08) | 0.143 |
| BMI, kg/m2 | 20.8 (18.7–23.7) | 18.3 (15.9–22.3) | 0.016 | 1.05 (0.85–1.31) | 0.643 |
| APACHE II score | 25.0 (21.0–29.5) | 25.5 (22.0–30.3) | 0.459 | ||
| Charlson Comorbidity Index | 2 (1–3) | 2 (1–3) | 1.000 | ||
| Blood culture positive | 21 (23.6) | 4 (18.2) | 0.777 | ||
| Permanent tracheostomy status | 26 (29.2) | 2 (9.1) | 0.052 | 0.35 (0.04–3.02) | 0.340 |
| Nasogastric tube insertion status | 30 (33.7) | 8 (36.4) | 0.814 | ||
| Invasive ventilation | 58 (65.2) | 19 (86.4) | 0.053 | 4.02 (0.68–23.76) | 0.124 |
| ARDS | 21 (23.6) | 8 (36.4) | 0.222 | ||
| Use of antibiotics within 3 months | 37 (41.6) | 12 (54.5) | 0.273 | ||
| MDR pathogen | 34 (38.2) | 19 (86.4) | < 0.001 | 17.43 (1.96–155.40) | 0.010 |
| MRSA | 8 (9) | 10 (45.5) | < 0.001 | ||
| CRAB | 16 (18) | 7 (31.8) | 0.238 | ||
| Bedridden status | 44 (49.4) | 6 (27.3) | 0.061 | 0.24 (0.05–1.13) | 0.071 |
| Brain problema | 69 (77.5) | 15 (68.2) | 0.36 | ||
| Diabetes mellitus | 20 (22.5) | 7 (31.8) | 0.36 | ||
| Hypertension | 37 (41.6) | 7 (31.8) | 0.402 | ||
| Acute kidney injury | 27 (30.3) | 4 (18.2) | 0.255 | ||
| Albumin, g/dL | 2.6 (2.3–2.9) | 2.0 (1.7–2.2) | < 0.001 | ||
| Albumin < 2.15 g/dL | 13 (14.6) | 16 (72.7) | < 0.001 | 28.05 (5.47–143.75) | < 0.001 |
| Total bilirubin, mg/dLb | 0.5 (0.3–0.8) | 0.6 (0.4–0.7) | 0.627 | ||
| LDH, IU/L | 239 (185.5–307.5) | 258 (200.5–367.0) | 0.184 | ||
| CRP, mg/dL | 13.0 (7.3–23.6) | 16.3 (12.8–21.3) | 0.151 | ||
| NT-ProBNP pg/mL | 1337 (410–4462) | 2909.5 (1302.5–10,555.3) | 0.124 | ||
| Triglyceride, mg/dLc | 76.0 (55.0–106.3) | 54.0 (43.0–83.0) | 0.034 | ||
| ICU length of stay | 7 (3–14.5) | 5.5 (3.5–19) | 0.801 | ||
Values are presented as numbers (percentages), and as median (interquartile range), unless otherwise indicated. OR, odds ratio; CI, confidence interval; BMI, body mass index; APACHE, acute physiology and chronic health evaluation; ARDS, acute respiratory distress syndrome; MDR, multiple-drug resistant; MRSA, methicillin-resistant Staphylococcus aureus; CRAB, carbapenem-resistant Acinetobacter baumannii; LDH, lactate dehydrogenase; CRP, C-reactive protein; NT-ProBNP, N-terminal prohormone of brain natriuretic peptide; ICU, intensive care unit; aneurodegenerative disorders and stroke; bFive missing values; cFourteen missing values
Fig. 2a, b Kaplan-Meier survival analysis of mortality and ICU length of stay according to identification of MDR pathogen and albumin levels
Distribution of isolated sputum culture pathogens within 48 h after admission
| Pathogen identified | |
|---|---|
| Gram-positive pathogen | |
| | 20 (27.0) |
| MSSA | 2 (2.7) |
| MRSA | 18 (24.3) |
| | 5 (6.8) |
| Gram-negative pathogen | |
| | 24 (32.4) |
| | 2 (2.7) |
| | 7 (9.5) |
| | 1 (1.4) |
| | 2 (2.7) |
| | 5 (6.8) |
| | 1 (1.4) |
| | 4 (5.4) |
|
| 3 (4.1) |
| MDR pathogen | 49 (66.2) |
| MRSA | 18 (24.3) |
| ESBL producing | 7 (9.5) |
| MDR- | 1 (1.4) |
| CRAB | 23 (31.1) |
Values are presented as numbers (percentages) unless otherwise indicated; MSSA, methicillin-susceptible Staphylococcus aureus; MRSA, methicillin-resistant Staphylococcus aureus; MDR, multiple-drug-resistant; ESBL, extended-spectrum beta-lactamases; CRAB, carbapenem-resistant Acinetobacter baumannii
Risk factors for MDR pathogens in patients who transferred from long-term care beds in institutions and hospitals
| Variable | Univariate | Multivariate | |||
|---|---|---|---|---|---|
| MDR negative ( | MDR positive ( |
|
|
| |
| Male sex | 30 (51.7) | 41 (77.4) | 0.005 | 2.65 (1.02–6.93) | 0.046 |
| Age, years | 78 (70.8–82) | 79 (71–84) | 0.372 | 1.02 (0.97–1.07) | 0.373 |
| BMI, kg/m2 | 20.8 (19.4–25.3) | 19.2 (17.5–22.7) | 0.005 | 0.9 (0.80–1.02) | 0.102 |
| Permanent tracheostomy status | 17 (29.3) | 11 (20.8) | 0.300 | ||
| Nasogastric tube insertion status | 16 (27.6) | 22 (41.5) | 0.123 | ||
| Invasive ventilation | 34 (58.6) | 43 (81.1) | 0.010 | 2.74 (1.02–7.32) | 0.045 |
| Bedridden status | 25 (43.1) | 25 (47.2) | 0.667 | ||
| Brain problema | 46 (79.3) | 38 (71.7) | 0.350 | ||
| Use of antibiotics within 3 months | 16 (27.6) | 33 (62.3) | < 0.001 | 3.23 (1.32–7.90) | 0.010 |
| Diabetes mellitus | 16 (27.6) | 11 (20.8) | 0.402 | ||
| Hypertension | 25 (43.1) | 19 (35.8) | 0.435 | ||
| Chronic pulmonary disease | 7 (12.1) | 13 (24.5) | 0.088 | ||
| Acute kidney injury | 19 (32.8) | 12 (22.6) | 0.235 | ||
| Albumin < 2.15 g/dL | 8 (13.8) | 21 (39.6) | 0.002 | 2.85 (0.98–8.24) | 0.054 |
Values are presented as numbers (percentages), and as median (interquartile rage), unless otherwise indicated; MDR, multiple-drug-resistant; OR, odds ratio; CI, confidence interval; BMI, body mass index; aneurodegenerative disorders and stroke